<DOC>
	<DOC>NCT00545857</DOC>
	<brief_summary>A study to examine the effect of pioglitazone on the course of new onset type 1 diabetes mellitus.</brief_summary>
	<brief_title>Effect of Pioglitazone on the Course of New Onset Type 1 Diabetes Mellitus</brief_title>
	<detailed_description>Thiazolidinediones have been shown to reduce the development of diabetes mellitus in animal models of type 1 diabetes and to reduce the death of beta cells (cells that make insulin) in petri dishes. Pioglitazone is a thiazolidinedione currently approved for the treatment of type 2 diabetes. This study explores the question of whether pioglitazone can preserve beta cell function in patients with recently diagnosed type 1 diabetes mellitus.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Patients with type 1 diabetes mellitus diagnosed within 4 months Age &gt; 6 years of age Ability to swallow capsule Signed informed consent / assent Other illnesses</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Type 1 diabetes</keyword>
	<keyword>Insulin dependent diabetes</keyword>
	<keyword>Juvenile onset diabetes</keyword>
	<keyword>pioglitazone</keyword>
</DOC>